Pfizer's Q2 earnings beat and 18% non-COVID growth highlight a successful business transition, yet shares remain range-bound as investors prioritize dividend stability over growth expectations.
Pfizer beat Q2 estimates and raised full-year revenue guidance on strong non-COVID growth and expanded cost cuts, but the muted share reaction and conservative valuation target temper the bullish case.
Bristol Myers Squibb guided 2026 revenue lower on a 12-16% decline in its legacy portfolio, which is structurally bearish despite its Growth Portfolio offset.
Merck is highlighted as posting stronger near-term growth but faces Keytruda patent cliff concentration risk, leaving a balanced outlook.
Eli Lilly is named as a dominant GLP-1 market player, but no new company-specific development is discussed.
Novo Nordisk is mentioned as a GLP-1 market leader and participant in the Metsera bidding war, but no direct financial update is provided.
Pfizer shares remain stagnant near $28 despite a strong Q2 earnings beat and raised full-year guidance. While non-COVID revenue grew 18% and cost-cutting initiatives continue, the market remains cautious, pricing the stock at a modest 9.9x forward earnings as investors weigh the company's long-term pipeline against looming patent cliffs.
The market is exercising caution due to the end of the COVID-era windfall and concerns regarding future patent cliffs, leading investors to favor the dividend yield over aggressive growth projections.
Pfizer trades at a forward P/E of roughly 9.9x, similar to Bristol Myers Squibb but significantly lower than Merck, which trades at 23x due to higher near-term growth expectations.